The company's revenue for the March 2026 quarter climbed to ₹7,474.66 crores, representing a 31.89% YoY jump and a sequential growth of 4.29% from the December 2025 quarter. This performance underscores Lupin's strengthening position in both domestic and international markets, driven by robust product launches, market share gains, and operational excellence across its manufacturing facilities.
Following the results announcement, Lupin's stock has demonstrated resilience, trading at ₹2,377.90 as of May 08, 2026, though experiencing a marginal single-day decline of 3.33%. Over longer timeframes, the stock has rewarded investors handsomely, delivering 18.52% returns over the past year and an exceptional 224.74% gain over three years, significantly outperforming the broader market indices.
Financial Performance: Margin Expansion Drives Profitability Surge
Lupin's Q4 FY26 results reflect a company firing on all cylinders, with revenue acceleration complemented by significant margin expansion. Net sales grew 4.29% QoQ from ₹7,167.52 crores in Q3 FY26 to ₹7,474.66 crores in Q4 FY26, whilst the YoY comparison reveals an even more impressive 31.89% growth trajectory from ₹5,667.13 crores in Q4 FY25.
The operating profit (PBDIT excluding other income) for Q4 FY26 reached ₹2,485.58 crores, marking the highest quarterly operating profit in the company's recent history. The operating margin expanded to 33.63%, up from 31.86% in the previous quarter and a substantial 985 basis points higher than the 23.75% recorded in Q4 FY25. This margin expansion reflects improved product mix, operational efficiencies, and better pricing realisation across key markets.
The profit after tax (PAT) margin improved dramatically to 19.87% in Q4 FY26, compared to 16.63% in Q3 FY26 and 14.07% in Q4 FY25. This 580 basis points YoY expansion in PAT margin demonstrates the operating leverage inherent in Lupin's business model and the company's ability to translate top-line growth into bottom-line profitability.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin |
|---|---|---|---|---|---|
| Mar'26 | 7,474.66 | +4.29% | 1,460.34 | +24.23% | 33.63% |
| Dec'25 | 7,167.52 | +1.70% | 1,175.55 | -20.46% | 31.86% |
| Sep'25 | 7,047.51 | +12.43% | 1,477.92 | +21.24% | 34.27% |
| Jun'25 | 6,268.34 | +10.61% | 1,219.03 | +57.80% | 28.02% |
| Mar'25 | 5,667.13 | -1.74% | 772.52 | -9.66% | 23.75% |
| Dec'24 | 5,767.71 | +1.67% | 855.16 | +0.30% | 24.13% |
| Sep'24 | 5,672.73 | — | 852.63 | — | 24.38% |
Employee costs for Q4 FY26 stood at ₹1,242.69 crores, up 8.68% QoQ from ₹1,143.28 crores, reflecting the company's continued investment in talent acquisition and retention. Despite this increase, the company maintained strong cost discipline, with employee costs as a percentage of sales declining from 15.95% in Q3 FY26 to 16.63% in Q4 FY26, demonstrating improving productivity metrics.
Operational Excellence: Superior Capital Efficiency Signals Quality Turnaround
Lupin's operational transformation is perhaps best captured by its return on equity (ROE) metric, which surged to an impressive 22.03% in the latest period, up significantly from the historical average of 9.89%. This exceptional ROE—more than double the company's historical average—demonstrates management's success in generating superior returns on shareholder capital, a critical indicator of sustainable value creation in the pharmaceutical sector.
Key Operational Strengths
Exceptional ROE Performance: The company's ROE of 22.03% represents outstanding capital efficiency, placing Lupin amongst the top-tier performers in the Indian pharmaceutical industry. This dramatic improvement from the average ROE of 9.89% signals a fundamental shift in the company's profitability profile and operational effectiveness.
Margin Leadership: Operating margins of 33.63% (excluding other income) position Lupin favourably within its peer group, reflecting superior pricing power, favourable product mix, and operational excellence across its global manufacturing footprint.
The company's return on capital employed (ROCE) similarly improved to 27.93% in the latest period, substantially higher than the historical average of 10.75%. This metric, which measures how efficiently the company generates profits from its capital base, underscores the quality of Lupin's earnings and the sustainability of its business model.
From a balance sheet perspective, Lupin maintains a conservative financial structure with negligible net debt. The company reported long-term debt of ₹1,766.23 crores as of March 2025, whilst maintaining healthy cash reserves and current assets of ₹16,798.58 crores. This strong balance sheet provides ample flexibility for strategic investments, research and development initiatives, and potential acquisitions.
The debt-to-EBITDA ratio of 3.07 (on average) and an EBIT-to-interest coverage ratio of 6.50x indicate comfortable debt servicing capabilities. Shareholder funds stood at ₹17,203.50 crores as of March 2025, up from ₹14,290.29 crores in the previous year, reflecting the company's strong internal accruals and retained earnings.
Product Portfolio Dynamics: Diversified Revenue Streams Drive Growth
Lupin's growth trajectory is underpinned by a well-diversified product portfolio spanning branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company's presence across multiple therapeutic areas—including cardiovascular, diabetology, respiratory, anti-infectives, gastro-intestinal, and central nervous system—provides resilience against therapeutic area-specific headwinds.
Revenue Mix Advantage
Whilst specific geographic revenue breakdowns were not disclosed in the quarterly results, Lupin's historical strength in the US generics market, combined with growing contributions from India formulations and emerging markets, creates a balanced revenue profile. The company's investments in complex generics and specialty products are beginning to yield results, as evidenced by the sustained margin expansion witnessed over the past four quarters.
Other income for Q4 FY26 stood at ₹140.71 crores, up from ₹114.70 crores in Q3 FY26 and ₹56.95 crores in Q4 FY25. Whilst other income constitutes a relatively modest portion of total income (approximately 5.35% of operating profit), the sequential and year-on-year increases suggest improving treasury management and potential gains from strategic investments.
Interest expenses for Q4 FY26 were ₹120.16 crores, up from ₹114.98 crores in Q3 FY26 and ₹89.10 crores in Q4 FY25. The increase in interest costs reflects higher working capital requirements to support the company's revenue growth, though the absolute burden remains manageable given the strong EBIT generation.
Industry Leadership: How Lupin Compares to Peers
Within the Indian pharmaceutical and biotechnology sector, Lupin occupies a prominent position with a market capitalisation of ₹1,10,873 crores, ranking fourth amongst its peer group. The company's valuation metrics reflect a balanced positioning—neither the most expensive nor the cheapest—suggesting market recognition of both its growth potential and execution risks.
| Company | P/E Ratio (TTM) | P/BV Ratio | ROE (%) | Dividend Yield | Debt/Equity |
|---|---|---|---|---|---|
| Lupin | 22.61x | 5.73x | 9.89% | 0.49% | 0.00 |
| Sun Pharma. Inds. | 36.19x | 5.65x | 15.21% | 0.90% | -0.29 |
| Divi's Lab. | 69.98x | 11.51x | 17.24% | 0.45% | -0.21 |
| Torrent Pharma | 63.83x | 17.43x | 22.06% | 0.67% | 0.24 |
| Cipla | 23.12x | 3.34x | 14.59% | — | -0.24 |
| Dr Reddy's Labs | 19.59x | 3.03x | 15.78% | 0.61% | 0.00 |
Lupin's price-to-earnings (P/E) ratio of 22.61x stands at a significant discount to the sector average of approximately 43x, and well below premium peers like Divi's Laboratories (69.98x) and Torrent Pharma (63.83x). This valuation gap exists despite Lupin's improving fundamentals, suggesting potential for re-rating as the market gains confidence in the sustainability of the company's turnaround.
The company's price-to-book value (P/BV) ratio of 5.73x is broadly in line with Sun Pharma (5.65x) but lower than Divi's (11.51x) and Torrent (17.43x). Given Lupin's improving ROE trajectory—now at 22.03%, comparable to Torrent's 22.06%—the current P/BV multiple appears reasonable and could justify expansion if the company sustains its current profitability levels.
Lupin's historical ROE of 9.89% has lagged peers, with Sun Pharma at 15.21%, Cipla at 14.59%, and Dr Reddy's at 15.78%. However, the latest ROE of 22.03% suggests Lupin is now operating at or above peer levels, a development that may not yet be fully reflected in the valuation multiples. The dividend yield of 0.49% is modest compared to Sun Pharma's 0.90%, reflecting the company's preference to retain earnings for growth investments rather than distribute cash.
Valuation Analysis: Attractive Entry Point Despite Recent Rally
At the current market price of ₹2,377.90, Lupin trades at a P/E ratio of 22.61x based on trailing twelve-month (TTM) earnings, representing a substantial discount to the industry P/E of 35x. This 35% valuation discount to the sector appears unjustified given the company's recent operational momentum, margin expansion, and improving return ratios.
The EV/EBITDA multiple of 14.69x and EV/EBIT of 17.76x suggest reasonable valuations when contextualised against the company's growth profile. With a five-year sales CAGR of 11.42% and EBIT CAGR of 33.60%, Lupin's PEG ratio of 0.31x indicates the stock is trading well below its growth rate—a classic indicator of undervaluation.
The company's valuation grade has evolved favourably, currently rated "Very Attractive" after transitioning from "Attractive" on October 01, 2025. This upgrade reflects the market's growing recognition of Lupin's improved fundamentals and sustainable business model. The stock's 52-week range of ₹1,838.65 to ₹2,492.00 shows the current price is positioned 29.33% above the low and just 4.58% below the high, suggesting limited downside risk whilst maintaining upside potential.
Shareholding Pattern: Institutional Confidence Building Steadily
Lupin's shareholding structure reflects a stable promoter base combined with growing institutional participation, a combination that typically supports long-term value creation. Promoter holding stood at 46.86% as of March 2026, marginally declining from 46.89% in December 2025 and 46.92% in March 2025. This minor reduction of 6 basis points over the year is insignificant and reflects normal variations rather than any strategic divestment.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 46.86% | 46.89% | 46.90% | 46.90% | -0.03% |
| FII Holding | 21.71% | 21.49% | 20.49% | 21.25% | +0.22% |
| Mutual Fund Holding | 16.93% | 18.01% | 20.57% | 19.35% | -1.08% |
| Insurance Holdings | 6.12% | 5.59% | 4.44% | 4.64% | +0.53% |
| Other DII Holdings | 2.27% | 1.99% | 1.55% | 1.57% | +0.28% |
| Non-Institutional | 6.11% | 6.03% | 6.06% | 6.28% | +0.08% |
Foreign institutional investor (FII) holdings increased to 21.71% in Q4 FY26 from 21.49% in Q3 FY26, marking the second consecutive quarter of FII accumulation after a dip to 20.49% in September 2025. This sequential increase of 22 basis points, whilst modest, signals renewed foreign investor interest in Lupin's equity story, likely driven by the improving financial performance and attractive valuations.
Mutual fund holdings witnessed a decline to 16.93% in March 2026 from 18.01% in December 2025, representing a reduction of 108 basis points. This follows a peak of 20.57% in September 2025, suggesting some profit booking by domestic institutional investors after the stock's strong rally. Despite this reduction, the absolute level of mutual fund ownership remains healthy at nearly 17%, indicating continued conviction amongst domestic asset managers.
Insurance company holdings demonstrated a positive trend, increasing to 6.12% from 5.59% in the previous quarter—a gain of 53 basis points. This marks a reversal from the decline witnessed between June and September 2025, when insurance holdings fell from 4.64% to 4.44%. The renewed accumulation by insurance companies, known for their long-term investment horizon, bodes well for stock stability.
Overall institutional holdings (FII + MF + Insurance + Other DII) stood at 47.03% as of March 2026, reflecting strong institutional participation. Notably, there is zero promoter pledging, eliminating a key governance risk that plagues many mid-cap Indian companies. The promoter group is led by Lupin Investments Private Limited (45.32%), with individual family members holding the balance.
Stock Performance: Stellar Three-Year Returns Despite Recent Volatility
Lupin's stock has delivered exceptional returns to long-term shareholders, though recent performance has been more volatile. The shares have generated an 18.52% return over the past year, substantially outperforming the Sensex's negative 3.74% return during the same period—translating to an alpha of 22.26 percentage points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +3.22% | +0.54% | +2.68% |
| 1 Month | +3.68% | -0.30% | +3.98% |
| 3 Months | +9.66% | -7.48% | +17.14% |
| 6 Months | +20.61% | -7.08% | +27.69% |
| Year-to-Date | +12.59% | -9.26% | +21.85% |
| 1 Year | +18.52% | -3.74% | +22.26% |
| 2 Years | +47.17% | +5.26% | +41.91% |
| 3 Years | +224.74% | +25.20% | +199.54% |
| 5 Years | +98.89% | +57.15% | +41.74% |
The stock's performance over longer timeframes is even more impressive. Over three years, Lupin has delivered returns of 224.74%, vastly outperforming the Sensex's 25.20% gain—an alpha of 199.54 percentage points. This exceptional performance reflects the market's recognition of Lupin's successful turnaround from the challenges faced in FY22 when the company reported a loss of ₹1,509 crores.
Over five years, the stock has generated returns of 98.89% compared to the Sensex's 57.15%, delivering an alpha of 41.74 percentage points. The two-year return of 47.17% (versus Sensex's 5.26%) further validates the strength of the company's recovery trajectory and operational improvements.
From a technical perspective, Lupin is currently in a "Bullish" trend as of May 06, 2026, having transitioned from "Mildly Bullish" on that date. The stock trades above all major moving averages—5-day (₹2,380.03), 20-day (₹2,331.54), 50-day (₹2,312.71), 100-day (₹2,229.85), and 200-day (₹2,101.25)—a configuration that typically supports continued upward momentum.
The stock's beta of 1.20 indicates higher volatility than the broader market, classified as a "High Beta Stock." Whilst this entails greater price fluctuations, it also offers the potential for outsized returns during favourable market conditions. The risk-adjusted return of 0.92 over one year, with a volatility of 20.13%, positions Lupin in the "LOW RISK HIGH RETURN" category—an attractive combination for risk-conscious investors.
Investment Thesis: Quality Turnaround at Reasonable Valuations
Lupin's investment case rests on four critical pillars, each of which has strengthened considerably following the Q4 FY26 results. The company's proprietary investment score of 87/100 reflects a "STRONG BUY" rating, supported by improving fundamentals across valuation, quality, financial trends, and technical indicators.
Valuation: At a P/E of 22.61x and P/BV of 5.73x, Lupin trades at a meaningful discount to both industry averages and premium peers despite comparable or superior recent performance metrics. The PEG ratio of 0.31x suggests the stock is significantly undervalued relative to its growth trajectory, offering potential for multiple expansion as the market gains confidence in earnings sustainability.
Quality: The company's quality grade of "Good" is supported by healthy long-term growth metrics (11.42% sales CAGR, 33.60% EBIT CAGR), zero promoter pledging, and robust institutional participation at 47.03%. The dramatic improvement in ROE from 9.89% (average) to 22.03% (latest) signals a fundamental shift in capital efficiency and business quality.
Financial Trend: The "Positive" financial trend designation reflects record quarterly metrics across revenue (₹7,474.66 crores), operating profit (₹2,485.58 crores), and net profit (₹1,460.34 crores). The consistent margin expansion over the past four quarters demonstrates operating leverage and improved business mix, whilst the 89.04% YoY profit growth validates the strength of the turnaround.
Technical Trend: The "Bullish" technical classification, with the stock trading above all major moving averages and multiple technical indicators flashing positive signals, provides additional confidence for entry. The delivery volume trends and institutional accumulation patterns suggest genuine buying interest rather than speculative activity.
Key Strengths & Risk Factors
✓ KEY STRENGTHS
- Exceptional ROE Improvement: ROE surged to 22.03% from historical average of 9.89%, demonstrating superior capital efficiency and sustainable profitability improvements.
- Record Operating Margins: Q4 FY26 operating margin of 33.63% represents the highest in recent quarters, reflecting improved product mix and operational excellence.
- Strong Revenue Momentum: Net sales growth of 31.89% YoY and 4.29% QoQ demonstrates robust demand across domestic and international markets.
- Attractive Valuation: Trading at 22.61x P/E versus industry average of 35x, offering 35% valuation discount despite improving fundamentals.
- Zero Promoter Pledging: Clean promoter holding of 46.86% with no pledging eliminates key governance risk.
- Institutional Confidence: Total institutional holdings of 47.03% with recent FII and insurance company accumulation signals professional investor confidence.
- Diversified Portfolio: Presence across multiple therapeutic areas and geographies provides revenue resilience and growth optionality.
⚠ KEY CONCERNS
- Rising Interest Burden: Interest expenses increased 34.84% YoY to ₹120.16 crores, reflecting higher working capital requirements.
- Mutual Fund Selling: MF holdings declined 108 bps QoQ from 18.01% to 16.93%, suggesting some institutional profit-booking.
- US Generic Pricing Pressure: Whilst not explicitly disclosed, the broader pharma sector faces ongoing pricing challenges in the US generics market.
- Regulatory Risks: Pharmaceutical manufacturing remains subject to stringent regulatory oversight with potential for compliance-related disruptions.
- High Beta Volatility: Beta of 1.20 indicates greater price volatility than the market, requiring tolerance for short-term fluctuations.
- Modest Dividend Yield: Dividend yield of 0.49% is below peer average, limiting income appeal for dividend-focused investors.
- Historical ROE Weakness: Despite recent improvement, the historical average ROE of 9.89% remains below peer levels, requiring sustained execution to maintain current performance.
Outlook: What Lies Ahead for Lupin
Looking ahead, Lupin's trajectory will be determined by its ability to sustain the margin expansion witnessed in FY26 whilst continuing to drive top-line growth across its diversified portfolio. The company's focus on complex generics, specialty products, and biosimilars should support premium pricing and margin resilience, though execution risks remain.
POSITIVE CATALYSTS
- Sustained Margin Expansion: Operating margins sustaining above 32-33% would validate business model improvements and support earnings upgrades.
- US Market Share Gains: Market share expansion in key US generic products could drive incremental revenue growth.
- New Product Launches: Pipeline of complex generics and specialty products reaching commercialisation stage.
- Valuation Re-rating: Sustained strong performance could trigger P/E multiple expansion towards industry average of 35x.
- Institutional Accumulation: Continued FII and insurance company buying would provide price support and reduce volatility.
RED FLAGS TO MONITOR
- Margin Compression: Any sequential decline in operating margins below 30% would raise concerns about sustainability.
- Revenue Growth Deceleration: QoQ revenue growth slowing below 2-3% could signal demand weakness.
- Regulatory Actions: Warning letters or import alerts from US FDA on manufacturing facilities.
- Promoter Stake Reduction: Any significant decline in promoter holding below 45% would be a negative signal.
- Working Capital Deterioration: Sharp increases in receivables or inventory days indicating collection or demand issues.
The pharmaceutical sector's long-term growth drivers remain intact—ageing populations, rising healthcare spending in emerging markets, and the ongoing shift towards generic medicines in developed markets. Lupin's positioning across these growth vectors, combined with its improving operational metrics, provides a favourable backdrop for continued value creation.
The Verdict: Compelling Turnaround Story at Attractive Valuations
Score: 87/100
For Fresh Investors: Lupin presents an excellent opportunity to participate in a quality pharmaceutical turnaround story at reasonable valuations. The combination of record profitability, exceptional ROE improvement to 22.03%, operating margin expansion to 33.63%, and a 35% valuation discount to the industry creates a compelling risk-reward proposition. Fresh accumulation is recommended with a 12-18 month investment horizon, building positions on any dips towards ₹2,250-2,300 levels.
For Existing Holders: Continue holding with conviction. The Q4 FY26 results validate the sustainability of the turnaround, and the stock's technical strength (trading above all moving averages) supports the bullish narrative. Existing investors should maintain full positions and consider averaging up on strength, as the valuation gap versus peers provides significant upside potential for multiple expansion.
Fair Value Estimate: ₹2,750-2,850 (16-20% upside from current levels), based on 28-30x P/E on FY27 estimated earnings, representing convergence towards industry average multiples as the market gains confidence in earnings sustainability.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Investments in equity markets are subject to market risks, and investors may lose part or all of their invested capital.
